Clinical Trial: Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-2).
Posted 11 January 2013 - 08:29 AM
The primary objective is to demonstrate the effect of macitentan on the reduction of the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcers (DU). Clinicaltrials.gov. 12/18/12. (Also see: Digital Ulcers)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager
ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)